Dexpramipexole dihydrochloride Catalog No.:M9926-2 A-438079 partially but significantly prevented

A-438079 partially but significantly prevented the 6-OHDA-induced depletion of striatal DA stores

4-b]pyridin-3-yl)pyridin-2-yl]piperazin-2-yl]-3-methylbutan-2-ol

7Sodium Channel inhibitor1 demonstrated concentration-dependent efficacy in preclinical behavioral pain models

ZLN024 directly activates recombinant AMPK α1β1γ1 and its homologue α2β1γ1 in a concentration-dependent manner

including T315I

Dexpramipexole dihydrochloride Catalog No.:M9926-2 A-438079 partially but significantly preventedDexpramipexole, also known as KNS 760704 and (R) Pramipexole, is under development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS. Dexpramipexole is a low molecular weight, water soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well